Introduction {#Sec1}
============

Total hip arthroplasty (THA) is generally considered one of the most successful orthopedic surgical procedures for relieving pain, restoring hip function, and improving quality of life in patients with osteoarthritis (OA) \[[@CR1], [@CR2]\]. Enhancement in THA has led to faster functional recovery, shorter length of hospital stay, and higher patient satisfaction \[[@CR3]\]. Among these factors, different surgical approaches can also affect the clinical outcomes after THA \[[@CR4]\]. The lateral approach (LA) is the preferred procedure of approximately 42% of orthopedic surgeons worldwide \[[@CR5]\]. However, the lateral approach requires muscle splitting, and thus, the postoperative pain is more severe \[[@CR6]\].

The direct anterior approach (DAA) is an alternative surgical approach for THA. The DAA is less commonly used, although it is gaining popularity in recent years \[[@CR7]\]. Advocates of the DAA suggested that the DAA is an intermuscular and internervous approach with less muscle and soft-tissue dissection \[[@CR8]\]. Conversely, surgeons who favor the LA cite advantages of extensile exposure with low rates of postoperative instability \[[@CR9]\]. Several randomized controlled trials (RCTs) have compared the DAA to the lateral approach for THA. Many of these studies contained relatively small samples and demonstrated inconsistent outcomes \[[@CR7]\]. This uncertainty leaves the determination of which surgical approach to adopt to the preference of the surgeons. Mjaaland et al. \[[@CR10]\] reported that the DAA caused less pain but higher postoperative levels of creatine kinase.

Two meta-analyses were recently published on this topic. Yue et al. \[[@CR11]\] conducted a meta-analysis and their final conclusion was that there is a lack of sufficient evidence to conclude whether the DAA or lateral approach is superior for THA patients. In this meta-analysis, the authors included non-RCTs and did not perform subgroup analysis. Therefore, there was a large heterogeneity in their meta-analysis. Putananon et al. \[[@CR12]\] conducted a network meta-analysis that compared the DAA, lateral, posterior, and posterior-2 approaches in THA. The results showed that the DAA and lateral approach ranked first and second, respectively, for THA. Network meta-analysis is an indirect analysis, and the evidence level was less than for direct meta-analysis.

Several more recent RCTs on this subject have been published without conclusive results. Thus, we undertook a further meta-analysis to evaluate whether the DAA is superior to the LA with respect to (1) Harris hip score; (2) pain score at 2 weeks, 6 weeks, and 12 weeks; (3) operation outcomes; and (4) complications and gait characteristics (velocity, stride length, and step length). We hypothesized that the DAA results in lower pain scores and less blood loss without increasing complications.

Material and methods {#Sec2}
====================

The systematic review and meta-analysis was in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines \[[@CR13]\] and AMSTAR (Assessing the methodological quality of systematic reviews) Guidelines.

Literature search {#Sec3}
-----------------

Three English databases, PubMed, Embase, and the Cochrane Library, were searched from inception to October 10, 2018, with the following search terms: "direct anterior approach" OR "anterior" OR "direct anterior" AND "lateral approach" OR "lateral" AND "total hip arthroplasty" OR "total hip replacement" OR "THA" OR "THR" OR ""Arthroplasty, Replacement, Hip "\[Mesh\]". There was no language or publication date restriction. We also searched reference lists of included trials and related meta-analyses to identify potentially omitted studies.

Inclusion criteria {#Sec4}
------------------

Participants: patients suffered from osteoarthritis and femur head necrosis and prepared for primary THAInterventions: the intervention group received the DAA for THAComparisons: the control group received LA for THAOutcomes: Harris hip score at final follow-up; VAS at 2 weeks, 6 weeks, and 12 weeks; operation time; total blood loss; transfusion rate; length of hospital stay; complications; and temporal and spatial gait characteristics (velocity, stride length, and step length). Included studies should include at least one of the above outcomes.Study design: RCTs were regarded as eligible for the study

Study selection {#Sec5}
---------------

Study selection was conducted by two reviewers. We removed the duplicates using Endnote X7 software (Thompson Reuters, CA, USA). According to the inclusion and exclusion criteria, we selected the included studies and downloaded the full text for data extraction. Discrepancies were reconciled through discussion or consultation with the author.

Data extraction {#Sec6}
---------------

Data in the included trials were extracted by two independent investigators. Disagreement between the two reviewers was settled by discussion and consultation with a third reviewer. The extracted information included (1) the basic characteristics of the included studies, including the authors, publication year, no. in the DAA and LA groups, mean age, female patients, BMI; (2) outcomes (Harris hip score at final follow-up; VAS at 2 weeks, 6 weeks, and 12 weeks; operation time, total blood loss, transfusion rate, length of hospital stay, and complications.); and (3) follow-up.

Assessment of methodological quality {#Sec7}
------------------------------------

Two authors assessed the quality of included studies independently with the risk-of-bias assessment tool outlined in the Cochrane Handbook. Seven domains were evaluated: (1) random sequence generation, (2) allocation concealment, (3) blinding of patients and personal information, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective reporting of risk, and (7) other biases.

Statistical analysis {#Sec8}
--------------------

Stata 12.0 (Stata Corp., College Station, TX) was used for statistical analysis, and a *P* value \< 0.05 was considered statistically significant. The risk ratio (RR) with 95% confidence intervals (CI) for the DAA compared with the LA was calculated for the transfusion rate and the occurrence of complications. Weighted mean differences (WMD) and 95% CI were calculated for continuous variables. A fixed effects model was chosen when there was no statistical evidence of heterogeneity (*I*^2^ \< 50%), and a random effects model was adopted if significant heterogeneity was found (*I*^2^ ≥ 50%). In addition, publication bias was assessed by funnel plots.

Results {#Sec9}
=======

Study characteristics {#Sec10}
---------------------

The process of study selection is shown in Fig. [1](#Fig1){ref-type="fig"}. Initially, we identified 205 records through database searching. After removing duplicates, only 158 papers remained for the next step. According to the inclusion criteria, 153 records were excluded. Finally, a total of 5 RCTs \[[@CR10], [@CR14]--[@CR17]\] met the inclusion criteria and were included in this meta-analysis.Fig. 1The flow diagram of study selection

Table [1](#Tab1){ref-type="table"} displays the detailed general characteristics of the included studies. A total of 475 patients were available for meta-analysis. The five eligible RCTs involved 236 hips that underwent the DAA and 239 hips that underwent the LA. All papers were published from 2009 to 2018. The sample size ranged from 16 to 84. The follow-up duration ranged from 3 to 48 months.Table 1General characteristic of the included studies. 1, Harris hip score at final follow-up; 2, VAS at 2 weeks, 6 weeks, and 12 weeks; 3, operation time, 4, total blood loss, 5, transfusion rate, 6, length of hospital stay, 7, complications, 8, temporal and spatial gait characteristics (velocity, stride length, and step length)AuthorCountryNo. of patients (*n*)Mean age (years)Female (%)BMI (kg/m^2^)OutcomesStudyFollow-upMjaaland 2015Norway84/8066.96627.651, 2, 3, 5, 7, 8RCTAt dischargeRestrepo 2010USA50/5067.269.827.61, 3, 4, 6, 9RCT48 monthsParvizi 2016USA50/5072.462281, 2, 5, 7, 8RCT12 monthsMayr 2009Austria16/176652.525.62, 3, 4, 5, 9RCT3 monthsZomar 2018Canada36/4260.25227.91, 2, 3, 4, 5RCT3 months

Risk of bias {#Sec11}
------------

The risk-of-bias summary and risk-of-bias graph are displayed in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}, respectively. The random sequence generation was described fairly well in four studies, and allocation concealment was described in three studies. In the remainder, this information was absent or unclear. Attrition bias, reporting bias, and other biases were all described fairly well and listed as a low risk of bias.Fig. 2Risk of bias summary for included studies. +, no bias; −, bias;?, bias unknownFig. 3Risk of bias graph: review authors' judgments about each risk of bias item presented as percentages across all included studies

Primary outcomes {#Sec12}
----------------

### Harris hip score at final follow-up {#Sec13}

A total of three studies totaling 342 THAs (DAA = 170, LA = 172) reported Harris hip scores at the final follow-up. There was no significant difference between the DAA and LA groups in terms of the Harris hip score at final follow-up (WMD = 0.63, 95% CI = − 2.54, 3.71, *P* = 0.689, Fig. [4](#Fig4){ref-type="fig"}). There was a large heterogeneity between the included studies (*I*^2^ = 98.1%); thus, we adopted a random effects model to pool the relevant data. Funnel plot analyses on the Harris hip score demonstrated symmetry, suggesting that bias was minimal (Fig. [5](#Fig5){ref-type="fig"}). Figure [6](#Fig6){ref-type="fig"} presents the results of sensitivity analyses. The findings for the Harris hip score were consistent after omitting each study in turn.Fig. 4Forest plot for comparing the DAA versus LA in terms of Harris hip score at final follow-upFig. 5Funnel plot for comparing the DAA versus LA in terms of Harris hip score at final follow-upFig. 6Sensitivity analysis of Harris hip score at final follow-up

### VAS at 2 weeks, 6 weeks, and 12 weeks {#Sec14}

There was no significant difference between the DAA and LA groups in terms of the VAS at 2 weeks (WMD = − 0.00, 95% CI − 0.16 to 0.15, *P* = 0.966, Fig. [7](#Fig7){ref-type="fig"}) and the VAS at 12 weeks (WMD = − 0.13, 95% CI − 0.37 to 0.12, *P* = 0.314, Fig. [7](#Fig7){ref-type="fig"}). Compared with the LA, the DAA was associated with a reduction in the VAS at 6 weeks (WMD = − 0.41, 95% CI − 0.63 to − 0.19, *P* = 0.000, Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Forest plot for comparing the DAA versus LA in terms of VAS at 2 weeks, 6 weeks, and 12 weeks

### Operation time {#Sec15}

Three trials totaling 364 patients provided data on operation time. There was no statistically significant difference between the DAA and LA groups in terms of the operation time (WMD = 4.53, 95% CI − 6.60 to 15.65, *P* = 0.425, Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Forest plot for comparing the DAA versus LA in terms of operation time

### Transfusion rate and total blood loss {#Sec16}

Three studies involving 364 patients provided data on the transfusion rate. Compared with the LA, the DAA had no benefit in reducing the transfusion rate after THA (RR = 0.71, 95% CI 0.43 to 1.18, *P* = 0.188, Fig. [9](#Fig9){ref-type="fig"}).Fig. 9Forest plot for comparing the DAA versus LA in terms of transfusion rate

Four trials totaling 397 patients provided data on total blood loss. Compared with the LA, the DAA reduced total blood loss in THA patients (WMD = − 45.73, 95% CI − 84.72 to − 6.02, *P* = 0.024, Fig. [10](#Fig10){ref-type="fig"}).Fig. 10Forest plot for comparing the DAA versus LA in terms of total blood loss

### Length of hospital stay {#Sec17}

Four trials totaling 442 patients provided data on the length of hospital stay. Compared with the LA, the DAA had no effect on reducing the length of hospital stay for THA patients (WMD = − 0.43, 95% CI − 1.06 to 0.20, *P* = 0.179, Fig. [11](#Fig11){ref-type="fig"}).Fig. 11Forest plot for comparing the DAA versus LA in terms of length of hospital stay

### Complications {#Sec18}

Five trials involving 475 patients provided data on complications. The results showed that there was no significant difference in complications between the DAA and LA groups (RR = 0.94, 95% CI 0.57 to 1.55, *P* = 0.820, Fig. [12](#Fig12){ref-type="fig"}).Fig. 12Forest plot for comparing the DAA versus LA in terms of the complications

### Temporal and spatial gait characteristics {#Sec19}

Only two studies involving 111 patients provided data on temporal and spatial gait characteristics (velocity, stride length, and step length). Compared with the LA, the DAA was associated with an increase in walking velocity (WMD = 5.01, 95% CI 2.32 to 7.70, *P* = 0.000, Fig. [13](#Fig13){ref-type="fig"}), stride length (WMD = 3.12, 95% CI 2.42 to 3.82, *P* = 0.000, Fig. [13](#Fig13){ref-type="fig"}), and step length (WMD = 4.09, 95% CI 1.03 to 7.14, *P* = 0.009, Fig. [13](#Fig13){ref-type="fig"}).Fig. 13Forest plot for comparing the DAA versus LA in terms of the temporal and spatial gait characteristics (velocity, stride length, and step length)

Discussion {#Sec20}
==========

Main findings {#Sec21}
-------------

Our systematic review and meta-analysis comprehensively and systematically reviewed the current available literature and found that in THA patients, compared with the LA, (1) the DAA significantly reduced VAS at 6 weeks and total blood loss; (2) the DAA significantly increased walking velocity, stride length, and step length in analyses of gait characteristics; and (3) the DAA had no benefit for Harris hip score, VAS at 2 weeks and 12 weeks, blood transfusion, length of hospital stay, and complications.

Comparison with other meta-analyses {#Sec22}
-----------------------------------

Only two meta-analyses of the DAA versus LA for THA have been published. However, differences between ours and previous ones should be noted. First, previous meta-analyses included no more than two RCTs and 106 patients that compared DAA versus LA in THA patients \[[@CR11], [@CR12]\]. In comparison, we included five RCTs totaling 475 patients. With the added statistical power of at least 369 patients, our current meta-analysis was the latest and the most comprehensive one. Yue et al. \[[@CR11]\] conducted a meta-analysis that compared the DAA and LA for THA. However, in this meta-analysis, they mixed RCTs and non-RCTs in the analyses. Thus, there was a large heterogeneity in their outcomes. Second, we applied further subgroup analysis and sensitivity analysis to provide a more credible estimate. Third, we compared gait characteristics between the DAA and LA.

Implications for clinical practice {#Sec23}
----------------------------------

Our meta-analysis showed that the DAA has a beneficial role in reducing postoperative pain and blood loss and increasing the function of hip joints. Therefore, the DAA might be the better approach for THA.

Furthermore, operator experience and learning curve are equally important factors. All of the included studies have reported that the operators have surpassed the learning curves; thus, the current evidence is limited, and further trials are warranted to identify differences in the learning curve between the two approaches.

First, we compared the Harris hip scores at the final follow-up. The results showed that the DAA and LA had similar hip function. Zomar et al. \[[@CR17]\] reported that there was no significant difference between the DAA and LA groups in terms of the patient-reported functional outcomes (*P* \> 0.05). However, Mirza et al. \[[@CR18]\] revealed that the DAA encourages earlier functional recovery than LA for THA patients. We found that the DAA only had a beneficial role in reducing VAS at 6 weeks. Mjaaland et al. \[[@CR10]\] compared pain scores between the DAA and LA groups in THA patients. The results showed that there were lower pain scores in the DAA group on all recorded days. Zomar et al. \[[@CR17]\] found no differences in pain VAS at 2 weeks and 12 weeks postsurgery between the DAA and LA groups.

Moreover, we found that the DAA was associated with a reduction in the total blood loss compared with the LA group. The DAA is an intermuscular and internervous approach without sacrificing muscle injury. Theoretically, the DAA could significantly reduce the approach-related blood loss. Tranexamic acid was routinely administered in THA, and thus, blood loss was not an important factor for hip function. Restrepo et al. \[[@CR14]\] estimated that blood loss was the same in the DAA and LA groups. We pooled total complications as the index for safety of these two approaches. The results showed that there was no significant difference between the groups in terms of complications.

Strength of current meta-analysis {#Sec24}
---------------------------------

A major strength of our meta-analysis was that we used gait characteristics (velocity, stride length, and step length) to analyze functional outcomes. The results showed that the DAA could increase walking velocity, stride length, and step length. All of the characteristics indicated that the DAA offers significant early advantages in functional recovery compared to the LA.

Limitations {#Sec25}
-----------

Our meta-analysis also has several limitations: (1) only five studies (475 THAs) were included in our meta-analysis. The statistical efficacy of our results would be more reliable if more studies had been included. (2) Some studies included RCTs that lacked details of the allocation concealment and blinding methods, which may affect the quality of evidence and strength of the recommendations. (3) Follow-ups of these studies were relatively short (maximum follow-up = 2 years), and long-term follow-ups are needed to compare hip function between the DAA and LA. (4) There was substantial heterogeneity between the included outcomes. We performed subgroup analysis and sensitivity analysis to decrease the heterogeneity; however, the overall heterogeneity was not changed after subgroup analysis or after sensitivity analysis.

Conclusion {#Sec26}
==========

In THA patients, compared with the LA, the DAA was associated with early functional recovery, low blood loss, and lower pain scores. There was no significant difference in Harris hip score or operation time between the DAA and LA groups. Considering the limitations of this meta-analysis, more high-quality RCTs are needed to further identify the effects of the DAA versus LA in THA patients.
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